Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03681093 · ClinicalTrials.gov registry record · Phase 3
Study of Efficacy of Fevipiprant in Patients With Nasal Polyposis and Asthma
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 98
- Enrollment target
NCT03681093 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 98 participants.
The verdict
NCT03681093, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 98 participants
- Enrollment target
Study Summary
A Phase 3b Proof-of-Concept study to evaluate the ability of fevipiprant 150 mg and 450 mg, compared with placebo, as add-on to nasal spray standard-of-care (SoC), in reducing endoscopic nasal polyp score in adult (≥ 18 years) patients with nasal polyposis and concomitant asthma.
Interventions
- DRUG Placebo
- DRUG Fevipiprant 150 mg
- DRUG Fevipiprant 450 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2019-03-26 |
| Est. Completion | 2020-06-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03681093
The ClinicalTrials.gov registry entry for NCT03681093 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 98 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03681093 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03681093 about?
NCT03681093 is a clinical study titled "Study of Efficacy of Fevipiprant in Patients With Nasal Polyposis and Asthma". A Phase 3b Proof-of-Concept study to evaluate the ability of fevipiprant 150 mg and 450 mg, compared with placebo, as add-on to nasal spray standard-of-care (SoC), in reducing endoscopic nasal polyp score in adult (≥ 18 years) patients with nasal polyposis and concomitant asthma.
What is the current status of trial NCT03681093?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 98 participants. The study started on 2019-03-26. Estimated completion is 2020-06-10.
What interventions are being tested in trial NCT03681093?
The interventions under investigation include: Placebo (DRUG), Fevipiprant 150 mg (DRUG), Fevipiprant 450 mg (DRUG).
Who is sponsoring clinical trial NCT03681093?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.